Phase 4
Completed N=19
Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
Vasoplegic Syndrome · Liver Transplant; Complications
Source: ClinicalTrials.gov NCT04054999 ↗
Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcomePrimary: Systemic Vascular Resistance (SVR) — 480; 410; 588; 420 dyne*sec/cm^5
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Systemic Vascular Resistance (SVR) |
480; 410; 588; 420; 650; 480 | — |
| PRIMARY Systolic Blood Pressure |
109; 110; 113; 101; 120; 111 | — |
| PRIMARY Diastolic Blood Pressure |
58; 55; 57; 55; 61; 55 | — |
| PRIMARY Vasopressin |
0.04; 0.04; 0.04; 0.04; 0.00; 0.02 | — |
| SECONDARY Post-operative Intensive Care Unit (ICU) Length of Stay |
1; 0 | — |
| SECONDARY Hospital Length of Stay |
7; 7 | — |
| SECONDARY Post-operative Complications |
1; 1; 0; 1; 0; 0 | — |
Eligibility Criteria
- Patients scheduled to undergo liver transplantation
- Patients able to read and understand consent document (if patient is unable to provide an informed consent, the Legally Authorized Representative will be ask to consent on behalf of the patient).
- SVR lower than 500 dynes-sec/cm-5 intraoperatively (this criterion must be met after consent intraoperatively)
Data sourced from ClinicalTrials.gov (NCT04054999). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.